LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

11.14

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.06

Max

11.39

Belangrijke statistieken
By Trading Economics
Inkomsten	7.7M -73M
Verkoop	929K 18M
Winstmarge	-401.495
Werknemers	260
EBITDA	7.4M -78M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+149.87% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-31M 813M
Vorige openingsprijs	11.14
Vorige sluitingsprijs	11.14

Nieuwssentiment

By Acuity

50%

151 / 345 Rangschikking in Healthcare

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 mei 2026, 23:46 UTC

Marktinformatie

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 mei 2026, 23:45 UTC

Marktinformatie

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 mei 2026, 23:42 UTC

Marktinformatie

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 mei 2026, 23:34 UTC

Marktinformatie

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 mei 2026, 23:11 UTC

Marktinformatie

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 mei 2026, 22:26 UTC

Acquisities, Fusies, Overnames

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 mei 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 mei 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 mei 2026, 22:11 UTC

Marktinformatie

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 mei 2026, 22:04 UTC

Marktinformatie

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 mei 2026, 08:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

23 mei 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

22 mei 2026, 21:10 UTC

Winsten

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2026, 19:47 UTC

Winsten

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mei 2026, 19:17 UTC

Marktinformatie

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mei 2026, 19:10 UTC

Marktinformatie

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mei 2026, 18:38 UTC

Marktinformatie

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mei 2026, 18:35 UTC

Acquisities, Fusies, Overnames

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mei 2026, 18:09 UTC

Marktinformatie

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mei 2026, 17:58 UTC

Marktinformatie

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

149.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.11 USD 149.87%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

151 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.